Skip to main content
Top
Published in: Discover Oncology 1/2021

Open Access 01-12-2021 | Osteosarcoma | Research

Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression

Authors: Riliang Cao, Jianli Shao, Wencai Zhang, Yongxin Lin, Zerong Huang, Zhizhong Li

Published in: Discover Oncology | Issue 1/2021

Login to get access

Abstract

High expression of long intergenic non-protein coding RNA 987 (LINC00987) is strongly associated with low overall survival of osteosarcoma; however, its role in osteosarcoma remains unclear. This study explored the biological function and underlying mechanism of LINC00987 in osteosarcoma. In this study, LINC00987 expression in osteosarcoma cells was analyzed using Cancer Cell Line Encyclopedia and qRT-PCR. The proliferation and migration and invasion in osteosarcoma cells were evaluated using Cell Counting Kit-8 and Transwell assays, respectively. Bioinformatic analysis was used to predict the LINC00987-bound miRNAs and miR-376a-5p-bound mRNAs. Dual-luciferase reporter assays were used to assess the interaction between miR-376a-5p, LINC00987, and forming-binding protein 1 (FNBP1). FNBP1 expression was measured by western blotting. LINC00987 was found to be upregulated in osteosarcoma cells. LINC00987 silencing suppressed proliferation, migration, and invasion of osteosarcoma cells. Additionally, miR-376a-5p expression was downregulated in osteosarcoma cells. miR-376a-5p knockdown reversed the effect of LINC00987 silencing on the biological function of osteosarcoma cell. miR-376a-5p was found to target LINC00987 and FNBP1. FNBP1protein level was increased in osteosarcoma cells; however, it was inhibited by silencing LINC00987 and enhanced by silencing miR-376a-5p. In conclusions, this study suggests LINC00987 silencing inhibits osteosarcoma cell proliferation, migration, and invasion by sponging miR-376a-5p to regulate FNBP1 expression. LINC00987 as a potential therapeutic target for osteosarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.PubMed Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.PubMed
2.
go back to reference Da W, Tao Z, Meng Y, Wen K, Zhou S, Yang K, Tao L. A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019. BMC Cancer. 2021;21:115.CrossRef Da W, Tao Z, Meng Y, Wen K, Zhou S, Yang K, Tao L. A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019. BMC Cancer. 2021;21:115.CrossRef
3.
go back to reference Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5:591–616.CrossRef Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5:591–616.CrossRef
4.
go back to reference Fang Y, Fullwood MJ. Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer. Genomics Proteomics Bioinform. 2016;14:42–54.CrossRef Fang Y, Fullwood MJ. Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer. Genomics Proteomics Bioinform. 2016;14:42–54.CrossRef
5.
go back to reference Rafiee A, Riazi-Rad F, Havaskary M, Nuri F. Long noncoding RNAs: regulation, function and cancer. Biotechnol Genet Eng Rev. 2018;34:153–80.CrossRef Rafiee A, Riazi-Rad F, Havaskary M, Nuri F. Long noncoding RNAs: regulation, function and cancer. Biotechnol Genet Eng Rev. 2018;34:153–80.CrossRef
6.
go back to reference Zhang W, Ren X, Qi L, Zhang C, Tu C, Li Z. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis. BMC Cancer. 2021;21:202.CrossRef Zhang W, Ren X, Qi L, Zhang C, Tu C, Li Z. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis. BMC Cancer. 2021;21:202.CrossRef
7.
go back to reference Tan J, Liang H, Yang B, Zhu S, Wu G, Li L, Liu Z, Li L, Qi W, Li S, Lin L. Identification and analysis of three hub prognostic genes related to osteosarcoma metastasis. J Oncol. 2021;2021:6646459.CrossRef Tan J, Liang H, Yang B, Zhu S, Wu G, Li L, Liu Z, Li L, Qi W, Li S, Lin L. Identification and analysis of three hub prognostic genes related to osteosarcoma metastasis. J Oncol. 2021;2021:6646459.CrossRef
8.
go back to reference Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, Taheri M. The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021;135:111217.CrossRef Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, Taheri M. The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021;135:111217.CrossRef
9.
go back to reference Sun K, Zhao J. A risk assessment model for the prognosis of osteosarcoma utilizing differentially expressed lncRNAs. Mol Med Rep. 2019;19:1128–38.PubMed Sun K, Zhao J. A risk assessment model for the prognosis of osteosarcoma utilizing differentially expressed lncRNAs. Mol Med Rep. 2019;19:1128–38.PubMed
10.
go back to reference Cao R, Shao J, Hu Y, Wang L, Li Z, Sun G, Gao X. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018;18:49.CrossRef Cao R, Shao J, Hu Y, Wang L, Li Z, Sun G, Gao X. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018;18:49.CrossRef
11.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRef
12.
go back to reference Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, Hatzigeorgiou AG. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44:D231-238.CrossRef Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, Hatzigeorgiou AG. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44:D231-238.CrossRef
13.
go back to reference Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.CrossRef Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.CrossRef
14.
go back to reference Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127-d131.CrossRef Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127-d131.CrossRef
15.
go back to reference Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.CrossRef Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.CrossRef
16.
go back to reference Wang C, Jing J, Cheng L. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Invest New Drugs. 2018;36:1116–32.CrossRef Wang C, Jing J, Cheng L. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Invest New Drugs. 2018;36:1116–32.CrossRef
17.
go back to reference Li G, Gao Y, Li K, Lin A, Jiang Z. Genomic analysis of biomarkers related to the prognosis of acute myeloid leukemia. Oncol Lett. 2020;20:1824–34.CrossRef Li G, Gao Y, Li K, Lin A, Jiang Z. Genomic analysis of biomarkers related to the prognosis of acute myeloid leukemia. Oncol Lett. 2020;20:1824–34.CrossRef
18.
go back to reference Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu J, Yang H, Chen Q, Chen M, Ye L, Wu H, Zhang Q. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.CrossRef Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu J, Yang H, Chen Q, Chen M, Ye L, Wu H, Zhang Q. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.CrossRef
19.
go back to reference Kushlinskii NE, Fridman MV, Braga EA. Long non-coding RNAs as competitive endogenous RNAs in osteosarcoma. Mol Biol (Mosk). 2020;54:776–801. Kushlinskii NE, Fridman MV, Braga EA. Long non-coding RNAs as competitive endogenous RNAs in osteosarcoma. Mol Biol (Mosk). 2020;54:776–801.
20.
go back to reference Yao S, Liu Y, Yao Z, Zhao Y, Wang H, Xu Y, Zhang J, Li J, Yang S. MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma. Oncol Lett. 2018;16:3169–76.PubMedPubMedCentral Yao S, Liu Y, Yao Z, Zhao Y, Wang H, Xu Y, Zhang J, Li J, Yang S. MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma. Oncol Lett. 2018;16:3169–76.PubMedPubMedCentral
21.
go back to reference Choudhury Y, Tay FC, Lam DH, Sandanaraj E, Tang C, Ang BT, Wang S. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012;122:4059–76.CrossRef Choudhury Y, Tay FC, Lam DH, Sandanaraj E, Tang C, Ang BT, Wang S. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012;122:4059–76.CrossRef
22.
go back to reference Huang P, Guo YD, Zhang HW. Identification of Hub genes in pediatric medulloblastoma by multiple-microarray analysis. J Mol Neurosci. 2020;70:522–31.CrossRef Huang P, Guo YD, Zhang HW. Identification of Hub genes in pediatric medulloblastoma by multiple-microarray analysis. J Mol Neurosci. 2020;70:522–31.CrossRef
23.
go back to reference Suman P, Mishra S, Chander H. High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas. Sci Rep. 2020;10:11543.CrossRef Suman P, Mishra S, Chander H. High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas. Sci Rep. 2020;10:11543.CrossRef
24.
go back to reference Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol. 2018;35:71.CrossRef Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol. 2018;35:71.CrossRef
25.
go back to reference Yamamoto H, Sutoh M, Hatakeyama S, Hashimoto Y, Yoneyama T, Koie T, Saitoh H, Yamaya K, Funyu T, Nakamura T, Ohyama C, Tsuboi S. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J Urol. 2011;185:1930–8.CrossRef Yamamoto H, Sutoh M, Hatakeyama S, Hashimoto Y, Yoneyama T, Koie T, Saitoh H, Yamaya K, Funyu T, Nakamura T, Ohyama C, Tsuboi S. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J Urol. 2011;185:1930–8.CrossRef
Metadata
Title
Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression
Authors
Riliang Cao
Jianli Shao
Wencai Zhang
Yongxin Lin
Zerong Huang
Zhizhong Li
Publication date
01-12-2021
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-021-00412-x

Other articles of this Issue 1/2021

Discover Oncology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine